The best way to predict future is to invent it.
- Alan Kay
01 November 2019:
Taktira is the name of a new initiative with a total volume of more than 3 million Euro that has been approved by the state NRW. Syntab Therapeutics will co-ordinate this initiative with eight partners in total. Gremse-IT, Aachen, TECO Development, Rheinbach, and Black Drop Biodrucker, Aachen, together with 4 academic partners, the Institute of Laboratory Animal Science, the Institute for Experimental Molecular Imaging and the Clinic for Gynaecology of the University Hospital Aachen as well as the Institute for Biological Chemistry of the University of Vienna are the partners. The consortium is up to develop a new class of immuno-oncologics activating the innate immune system while showing higher efficacy and better bioavailability than existing compounds.
28 October 2018:
Syntab Therapeutics has signed an agreement with Efficient Robotics GmbH, Kornwestheim, Germany, in order to create an innovative binder peptide unit capable to synthesize and screen thousands of potential binders within short time. With the help of Efficient Robotics’s microfluidics technology, this unit is up to be realized. A proof-of-principle has already been shown. The co-operation enables Syntab Therapeutics to realize novel immunooncologic drug molecules with strong binding specificities for diverse targets in short time.
14 October 2016:
Syntab Therapeutics is leading the project consortium I3-STM with a total volume of about 3 million Euro. The project is supported by EFRE and the state Northrhine-Westphalia. Next to Syntab, the companies Taros Chemicals, Dortmund, Gremse-IT, Aachen, and TECO Development, Rheinbach, co-operate with 3 academic partners, the Institute of Laboratory Animal Science, the Institute for Experimental Molecular Imaging as well as the Medical Clinic III of the University Hospital Aachen.